Trial Profile
Dose escalation study of ARN-509 with everolimus in patients with progressive metastatic castration-resistant prostate cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2014
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Everolimus
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 23 Jul 2014 New trial record